The high expression of AFAP1‐AS1 can affect the progression of various tumors, including nasopharyngeal carcinoma, renal cell carcinoma, liver cancer, colorectal cancer, etc.29, 30, 31Silencing AFAP1‐AS1 in gallbladder cancer cells can upregulate E‐cadherin, downregulate Twist1 and Vimentin, and inhibit the migration and invasion of nasopharyngeal carcinoma cells by inhibiting the EMT process.32 This evidence concerns the gene CDH1 and nasopharyngeal carcinoma.